The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

Regeneron Pharmaceuticals ... across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines ...

Its incidence varies by bispecific antibodies and disease subtype ... Bristol Myers Squibb (BMS), Janssen, Takeda, AbbVie, Regeneron, and Sanofi; and advisory board membership with Pfizer and Sanofi.

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... Linvoseltamab is an investigational BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape ... and common LC, the 1st symmetric format, the discovery that natural human IgG4 is bispecific ...

Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline ...

Regeneron also resubmitted the BLA for odronextamab, a bispecific antibody targeting CD20 and CD3, in R/R follicular lymphoma, to the FDA. The EC also approved Kevzara (sarilumab) for the ...